Phase 3 Lymphoma Trial, Recruiting (NCT04365036)

Phase 3 Lymphoma Trial, Recruiting NCT04365036 Sponsor: Sun Yat-sen University Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT04365036 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with extranodal natural killer/T-cell lymphoma, nasal type, confirmed by a tissue biopsy
People who have been newly diagnosed and whose disease is at an early stage (stage I or II)
People who have at least one measurable area of disease that can be assessed during the trial
People who are reasonably active and able to carry out daily activities (assessed using a standard medical scale — confirm with trial site)
People aged between 18 and 75 years old, with no other current cancer diagnosis
People whose major organs (such as heart, kidneys, and liver) are functioning adequately

Who may not be able to join:

People who have a serious complication called hemophagocytic syndrome, or a related condition called aggressive NK cell leukemia
People whose lymphoma has spread to the brain or spinal cord (the central nervous system)
People who have already received any treatment for their lymphoma, including chemotherapy, radiation therapy, immunotherapy, or biological therapy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0086-20-87342823

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04365036

Sponsor: Sun Yat-sen University

Phase: Phase 3

Status: Recruiting

Condition: Lymphoma

Trial contact: 0086-20-87342823

More information: https://clinicaltrials.gov/study/NCT04365036

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with extranodal natural killer/T-cell lymphoma, nasal type, confirmed by a tissue biopsy
People who have been newly diagnosed and whose disease is at an early stage (stage I or II)
People who have at least one measurable area of disease that can be assessed during the trial
People who are reasonably active and able to carry out daily activities (assessed using a standard medical scale — confirm with trial site)
People aged between 18 and 75 years old, with no other current cancer diagnosis
People whose major organs (such as heart, kidneys, and liver) are functioning adequately

Who may not be able to join:

People who have a serious complication called hemophagocytic syndrome, or a related condition called aggressive NK cell leukemia
People whose lymphoma has spread to the brain or spinal cord (the central nervous system)
People who have already received any treatment for their lymphoma, including chemotherapy, radiation therapy, immunotherapy, or biological therapy

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Sun Yat-sen University

Registry

ClinicalTrials.gov

Start date

3 May 2020

Est. completion

31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

progression free survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov